Speakers

Expand/Collapse

Alan Wookey
Companion Diagnostics & Oncology Scientific Advisor
Q2 Solutions

Track C - Day 1 AM

11:00 am | Panel Discussion: A Shared Vision: Building a Best-in-Class Model for Global CDx Clinical Trial Deployment

Alessandra Cesano
Chief Medical Officer
ESSA Pharma

Day One

Thursday 13th December 2018

3:50 pm |

Evidence Enabling Informed Biomarker Strategy Decision Making

6:00 pm | Chair’s Closing Remark & End of Day 1

4:00 pm | Panel Discussion: How to Know When a CDx & a Predictive Biomarker is Needed for a Drug

Track B - Day 1 AM

10:05 am |

Early Biomarker Decision-Making for Time-Efficient Clinical Planning

Track B - Day 1 PM

1:35 pm |

Defining Your Patient Population

Amy Gorman
Global Companion Diagnostics Commercial Strategy Director
Janssen

Andrea Schütte
Director, Liquid Biopsy Biobank
Indivumed, GmbH

Track A - Day 2 AM

12:00 pm | High Quality Liquid Biopsies- Capture the Molecular Reality

Andrea Stevens
Global CoDx Market Access Director
Janssen Inc.

Track C - Day 1 AM

12:30 pm | Panel Discussion: Cross-Functional Communication

Andrew Beck
Co-Founder & Chief Executive Officer
Path AI

Day Two

Thursday 13th December 2018

4:30 pm | Leveraging Machine Learning & AI in Translational Medicine

Angel Rodriguez
Medical Director
Natera Oncology

Track B - Day 2 AM

12:00 pm | Power of Tumor-Informed & Personalized Assays to Drive High Sensitivity

Anindya Sen
Director, Research & Development
Prevail Therapeutics

ED&I CDx Engage Workshop

Monday 27 September, 2021

9:10 am | Round Table Discussion: Effective Leadership & Mentorship Structures to Foster Diversity & Inclusion Across Your Organization

Anne-Marie Martin
Senior Vice President , Global Head of Experimental Medicine
GlaxoSmithKline

Track B - Day 1 PM

2:30 pm | Data Driven Companion Diagnostic Development

Antonella Cardone
Executive Director
European Cancer Patient Coalition

Track C - Day 2 PM

3:00 pm | Panel Discussion Demonstrating Clinical Utility to Engage with Payors & Secure Reimbursement

2:00 pm | Identifying Clinician and Patient Barriers to Guideline-Concordant Biomarker Testing

Arunthi Thiagalingam
Director, Pharmacology/ Translational Medicine
Spectrum Pharmaceuticals

Track A - Day 2 PM

2:00 pm | Overcoming Sample Quantity Limitations

Brian Baker
Senior Director, Regulatory Affairs (CDx)
Regeneron Pharmaceuticals

Track C - Day 1 PM

2:00 pm | Finding a Compatible Partner in the CDx Space

Brian Kelly
Vice President Global Biopharma and CDx Strategy
Caris Life Sciences

Track C - Day 2 AM

12:00 pm | Combining AI and Comprehensive Molecular profiling to deliver the next generation of Molecular Diagnostics

Candy Gee
Diversity & Inclusion Partner
Roche Diagnostic Operations

ED&I CDx Engage Workshop

Monday 27 September, 2021

11:00 am | Panel Discussion: Diversity, Equity, & Inclusion: Why Does This Matter, and What Does It Mean for the Future of Healthcare?

Carlee Hemphill
Lead Scientist
Labcorp Oncology

Cecília Schott
Vice President, Global Head Precision Medicine, Oncology Business Unit
Novartis

ED&I CDx Engage Workshop

Monday 27 September, 2021

11:00 am | Panel Discussion: Diversity, Equity, & Inclusion: Why Does This Matter, and What Does It Mean for the Future of Healthcare?

Charles Koyias
Associate Director, Global Medical Affairs, Oncology
AbbVie

Track C - Day 1 AM

12:30 pm | Panel Discussion: Cross-Functional Communication

Charles Mathews
Principal
ClearView Healthcare Partners

Track C - Day 2 PM

3:00 pm | Panel Discussion Demonstrating Clinical Utility to Engage with Payors & Secure Reimbursement

Chowdary Dondapati
Executive Director, Head of CDx Marketing (US)
Bayer Oncology

Track C - Day 2 AM

12:30 pm | Post Market Activities: Innovative Commercial Strategies for Rare Oncology Tumors

Chris Abbosh
Principal Clinical Fellow, AstraZeneca Clinical Fellowship
University College London

Track B - Day 2 PM

2:00 pm | ctDNA Response as an Earlier Indicator of Benefit & for MRD Monitoring

Chris Whelan
Associate Director & Head of Translational Genetics
Biogen

Track A - Day 2 AM

11:30 am | Driving Biomarker Discovery: The UK Biobank Pharma Proteomics Project

Christine Blinco
Global Director of Marketing, Oncology Diagnostics
GlaxoSmithKline

Track C - Day 1 AM

12:30 pm | Panel Discussion: Cross-Functional Communication

Christoph Majewski
Lifecycle Leader CDx
Roche Diagnostics

Day One

Thursday 13th December 2018

8:30 am | The Rapid Expansion of Companion Diagnostics is Impacting Us All - How Roche is Transforming in Response

Christopher Conn
Director, Companion Diagnostics Strategy Lead
AbbVie

Track C - Day 2 AM

11:30 am | Strategies & Considerations for CDx Development in Early Phase Oncology Studies

Cindy Perettie
Head of Roche Molecular Labs
Roche Diagnostic Solutions

ED&I CDx Engage Workshop

Monday 27 September, 2021

11:00 am | Panel Discussion: Diversity, Equity, & Inclusion: Why Does This Matter, and What Does It Mean for the Future of Healthcare?

Clara Montagut
Head, Gastrointestinal Cancer Unit, Medical Oncology
Hospital del Mar

Corrinne Danan
Executive Vice President, Partnerships Business Unit
HalioDx

Courtney Nicholson
Director Business Development
Abcam

Track A - Day 1 AM

12:00 pm | Partnering to Accelerate Biomarker Research and Validation Prior to Clinical Development

Craig Eagle
Chief Medical Officer
Guardant Health

ED&I CDx Engage Workshop

Monday 27 September, 2021

9:30 am | Panel Discussion: Challenges in Diversity, Equity, & Inclusion in Oncology Clinical Trials & Genomic Testing

Daniel Simon
Senior Vice President, Biopharma Business Development
Guardant Health

Day Two

Thursday 13th December 2018

9:00 am | Comprehensive Genomic Profiling Across the Continuum of Care: Are We There Yet?

Danielle Murphy
Director, Translational Oncology
Pfizer

Day Two

Thursday 13th December 2018

8:30 am | Working Together to Enable Solutions to Reach Patients: Maximizing the Utility of Data

David Portman
Chief Executive Officer, Chief Medical Officer
Sermonix Pharmaceuticals

Track B - Day 1 AM

11:30 am | From the Clinic to CDx: Navigating the Path of Clinical Trial Assay Selection & CDx Options for Targeted Oncology Therapies in Mid-Stage Development

Dawn McHugh
Senior Director Strategic Business Development
Personalis

Track A - Day 1 PM

2:30 pm | The Personalis NeXT PlatformTM for Oncology Precision Medicine

Deborah Shepard
Director, Biomarker Clinical Assay Lead
Pfizer

ED&I CDx Engage Workshop

Monday 27 September, 2021

12:00 pm | Transforming the Recruitment Process & Returning to Work in the Post-COVID19 Era – Further Accelerating Our Industry’s Journey to Becoming Truly Equal, Diverse & Inclusive

Dennis O’Malley
Senior Pathologist
NeoGenomics Laboratories

Track C - Day 1 PM

2:40 pm | Panel Discussion: Flow Cytometry as a Tool for New Biomarkers and Companion Diagnostics Based on Single Cell Protein Expression

Diane Da Silva
Associate Director of Translational Medicine
Parker Institute for Cancer Immunotherapy

Track A - Day 1 AM

1:00 pm | Panel Discussion: What’s Needed to Move the Needle in IO?

Don Bergstrom
Executive Vice President and Head of Research & Development
Relay Therapeutics

Track B - Day 1 PM

2:30 pm | Data Driven Companion Diagnostic Development

Dr. Scott Kopetz
Professor - Deputy Department Chair
MD Anderson Cancer Center

Elizabeth Attias
Chief Strategy & Development Officer
Sermonix Pharmaceuticals

ED&I CDx Engage Workshop

Monday 27 September, 2021

12:00 pm | Transforming the Recruitment Process & Returning to Work in the Post-COVID19 Era – Further Accelerating Our Industry’s Journey to Becoming Truly Equal, Diverse & Inclusive

Ellie Corigliano
Head of CDx Cell & Gene Therapies Oncology
GlaxoSmithKline

Day One

Thursday 13th December 2018

4:00 pm | Panel Discussion: How to Know When a CDx & a Predictive Biomarker is Needed for a Drug

ED&I CDx Engage Workshop

Monday 27 September, 2021

12:00 pm | Transforming the Recruitment Process & Returning to Work in the Post-COVID19 Era – Further Accelerating Our Industry’s Journey to Becoming Truly Equal, Diverse & Inclusive

Track B - Day 1 PM

2:00 pm | Use of NY-ESO-1 TCR T-Cell Therapy in Patients with Mixed Round Cell Liposarcoma Whose Tumors are NYESO-1 Positive

Erin Newburn
Director, Field Application Scientist
Personalis

Track A - Day 1 PM

2:30 pm | The Personalis NeXT PlatformTM for Oncology Precision Medicine

Eugean Jiwanmall
Senior Research Analyst for Medical Policy & Technology Evaluation
Independence Blue Cross

Track C - Day 2 PM

3:00 pm | Panel Discussion Demonstrating Clinical Utility to Engage with Payors & Secure Reimbursement

2:30 pm | Generating Proper Reliable Evidence to Translate New Medicines/Interventions to the Clinic – The Current Reimbursement Landscape

Evi Lianidou
Professor of Analytical Chemistry, Clinical Chemistry; Head, Laboratory of Analytical Chemistry, ACTC Lab
University of Athens

Track B - Day 1 AM

12:00 pm | Liquid Biopsy of EGFR Mutations in NSCLC Patients Before and After Osimertinib Therapy

Faswilla Sampson
Vice President of Operations
Personalized Medicine Coalition

ED&I CDx Engage Workshop

Monday 27 September, 2021

9:30 am | Panel Discussion: Challenges in Diversity, Equity, & Inclusion in Oncology Clinical Trials & Genomic Testing

Gary Riordan
CDx Regulatory Consultant
Sermonix Pharmaceuticals

Track B - Day 1 AM

11:30 am | From the Clinic to CDx: Navigating the Path of Clinical Trial Assay Selection & CDx Options for Targeted Oncology Therapies in Mid-Stage Development

Gavin Gordon
Vice President, Clinical Market Development
Akoya Biosciences

Track A - Day 2 PM

2:30 pm | A Spatial Biology Approach for Biomarker Studies In Immuno-Oncology

Gianni Ferreri
Product Development Leader
Roche Diagnostics Solutions

Greg Jones
Senior Director of Medical Affairs
Inivata

Track B - Day 2 PM

3:30 pm | Personalized ctDNA MRD Assays – Redefined

Jaime Boyle
Vice President, BioPharma Business Development
Guardant Health

ED&I CDx Engage Workshop

Monday 27 September, 2021

9:30 am | Panel Discussion: Challenges in Diversity, Equity, & Inclusion in Oncology Clinical Trials & Genomic Testing

James Hewitt
IVD Product Expert
TÜV SÜD

Track B - Day 1 AM

12:30 pm | Panel Discussion: Preparation & Planning for Regulatory Assessment

Janelle Schrag
Assistant Director, Research Programs
Association of Community Cancer Centers

Track C - Day 2 PM

2:00 pm | Identifying Clinician and Patient Barriers to Guideline-Concordant Biomarker Testing

Janine Ting Jansen
Senior Director of Inclusion & Diversity, North America
Teva Pharmaceuticals

ED&I CDx Engage Workshop

Monday 27 September, 2021

1:00 pm | Hanson Wade & Chair’s Closing Remarks

Jason Adams
Global Head of PHC Solutions Partnering
Roche Diagnostics Solutions

Jason Simon
VP Translational Research and Companion Diagnostics
Black Diamond Therapeutics Inc.

Javier Perez
Director, Precision Medicine, Companion Diagnostics
Regeneron Pharmaceuticals

Track C - Day 1 PM

2:00 pm | Finding a Compatible Partner in the CDx Space

Jaya Krishnan
Co-Founder
Genome Biologics

Day Two

Thursday 13th December 2018

5:00 pm | Utilizing AI Tools for CVD & Rare Disease Drug Development

Jeanine Roodhart
Oncology Specialist
UMC Utrecht

Track A - Day 1 AM

1:00 pm | Panel Discussion: What’s Needed to Move the Needle in IO?

Jeffrey Conroy
Chief Scientific Officer
OmniSeq

Jennifer Dacpano- Komansky
Director, Global Regulatory Affairs, Medical Devices
Novartis

Track B - Day 1 AM

12:30 pm | Panel Discussion: Preparation & Planning for Regulatory Assessment

Jennifer Giltnane
Principal Pathologist-Scientist, Lead of Translational Tissue Technology Lab
Genentech

Jennifer Higgins
Vice President, Public Affairs
Guardant Health

ED&I CDx Engage Workshop

Monday 27 September, 2021

9:30 am | Panel Discussion: Challenges in Diversity, Equity, & Inclusion in Oncology Clinical Trials & Genomic Testing

Jess Lambe
Director of CDx Partnering
Illumina

Day One

Thursday 13th December 2018

4:30 pm | A Powerful Combination: Best-in-Class, Distributed Genomic Profiling Meets Gold-Standard HRD Testing

Jill German
Head of Pathology Customer Area
Roche Diagnostic Solutions

ED&I CDx Engage Workshop

Monday 27 September, 2021

11:00 am | Panel Discussion: Diversity, Equity, & Inclusion: Why Does This Matter, and What Does It Mean for the Future of Healthcare?

Johan Baeck
Senior Vice President Clinical Development & Medical Affairs
Jounce Therapeutics

Track B - Day 1 AM

10:30 am | Incorporating Biomarkers in Early Clinical Development Strategy

John Ferbas
Director, Department of Medical Sciences
Amgen

Track C - Day 1 PM

2:40 pm | Panel Discussion: Flow Cytometry as a Tool for New Biomarkers and Companion Diagnostics Based on Single Cell Protein Expression

John Simmons
Global Vice President, Biopharma Business Development
Natera

Track B - Day 2 AM

12:00 pm | Power of Tumor-Informed & Personalized Assays to Drive High Sensitivity

John Wojcik
Director, Translational Pathology
Bristol-Myers Squibb

Jörg Engelbergs
Scientific-Regulatory Expert Targeted & Personalized Biomedicines
Paul-Ehrlich-Institut Federal Institute for Vaccines and Biomedicines

Track B - Day 1 AM

12:30 pm | Panel Discussion: Preparation & Planning for Regulatory Assessment

Joshua Curtin
Translational Research
Janssen

Joshua Xu
Branch Chief, National Center for Toxicological Research
US Food & Drug Administration

Track A - Day 1 AM

10:30 am | Reliable & Accurate TMB Measurements by NGS Panels for Precision Oncology

Jude O’Donnell
Head, Regulatory Strategy
Almac Diagnostic Services

Track B - Day 1 AM

11:00 am | Clinical Trial Assay & CDx Development in the Era of Precision Medicine – Planning for Success

Kashyap Patel
President
Community Oncology

Day One

Thursday 13th December 2018

8:00 am | Translational Case Study: Translational Development of IACS-6274, a Potent and Selective Glutaminase (GLS1) Inhibitor in Phase 1 Trials for Molecularly-Defined Subsets of Patients with Advanced Solid Tumors

9:30 am | Equity & Diversity in Precision Medicine: Better Drugs for Disease Heterogeneity in Diverse Populations

Kate Knobil
Chief Medical Officer
Agilent Technologies

Day Two

Thursday 13th December 2018

9:30 am | Mixed Models of Commercialization for Companion Diagnostics

Katherine Block
Director, Biomarker Sciences
Sangamo Therapeutics

ED&I CDx Engage Workshop

Monday 27 September, 2021

11:00 am | Panel Discussion: Diversity, Equity, & Inclusion: Why Does This Matter, and What Does It Mean for the Future of Healthcare?

Track C - Day 1 AM

10:30 am | Translating Oncology Successes into Outside Disease Indications

Katherine T Landschulz, PhD
Therapeutic Area Lead, Biomarker Solution Center
Labcorp Technology

Day One

Thursday 13th December 2018

9:00 am | Practical Strategies for Implementing an Effective Neurodegenerative Biomarker Program into Your Clinical Trial and Diagnostic Transition

Kathryn Lang
Vice President, Outcomes & Evidence
Guardant Health

ED&I CDx Engage Workshop

Monday 27 September, 2021

9:30 am | Panel Discussion: Challenges in Diversity, Equity, & Inclusion in Oncology Clinical Trials & Genomic Testing

Kaye Foster
Senior Advisor & Executive Coach
The Boston Consulting Group (BCG)

Day One

Thursday 13th December 2018

9:30 am | Equity & Diversity in Precision Medicine: Better Drugs for Disease Heterogeneity in Diverse Populations

ED&I CDx Engage Workshop

Monday 27 September, 2021

8:30 am | Hanson Wade & Chair’s Opening Remarks

Keith Wharton
Vice President, Medical Director
Ultivue

Track A - Day 1 AM

11:30 am | Innovative Biomarker Whole-Slide Imaging for Comprehensive Tissue Immunophenotyping Analysis

Kirsteen Maclean
Senior Director of Biomarker & Translational Strategy
Ultivue

ED&I CDx Engage Workshop

Monday 27 September, 2021

10:00 am | Panel Discussion: From Making Your Pledge to Implementation: How Is Your Organization Embedding Diversity, Equity & Inclusion Across All Internal Layers?

Kristina McGuire
Sr. Director and Head of CDx & Lab Operations
Regeneron

Track C - Day 1 AM

11:00 am | Panel Discussion: A Shared Vision: Building a Best-in-Class Model for Global CDx Clinical Trial Deployment

Krystin Meidell
Director, Global Regulatory Strategy
AbbVie

Track C - Day 1 AM

12:30 pm | Panel Discussion: Cross-Functional Communication

Lesley Farrington
Regulatory
Janssen

Lesli Kiedrowski
Director, Medical Affairs
Guardant Health

Lidija Pestic-Dragovich
Senior Director, Pharma Services & Pharma Alliance, PHC Solutions
Roche Diagnostics Solutions

Luca Quagliata
Vice President, Global Head of Medical Affairs
Thermo Fisher Scientific

Day Two

Thursday 13th December 2018

10:00 am | Reducing Time to Treatment Initiation in Precision Oncology: The Impact of Fast NGS Testing

Madhushree Ghosh
Vice President, Strategic Alliances & Projects BioPharma Services
NeoGenomics Laboratories

ED&I CDx Engage Workshop

Monday 27 September, 2021

8:40 am | How to Mentor Without Making It All About Yourself

Marc Yoskowitz
Executive Vice President & Chief Strategy Officer, Life Sciences
Tempus Labs

Track B - Day 1 PM

2:30 pm | Data Driven Companion Diagnostic Development

Marielena Mata
Senior Director & Diagnostic Lead
Pfizer

ED&I CDx Engage Workshop

Monday 27 September, 2021

9:10 am | Round Table Discussion: Effective Leadership & Mentorship Structures to Foster Diversity & Inclusion Across Your Organization

Mark Hellewell
International Product Manager, PHC Solutions - Oncology
Roche Diagnostics Solutions

Mark Kiel
Co-Founder & Chief Science Officer
Genomenon

Track C - Day 1 AM

10:05 am |

Clinical Strategies for Biomarker-Driven Trials

Track C - Day 1 PM

1:36 pm |

Navigating a Fast-Growing Companion Diagnostics Market

Mark Li
Chief Executive Officer
Resolution Bioscience

Day Two

Thursday 13th December 2018

9:30 am | Mixed Models of Commercialization for Companion Diagnostics

Mark Stewart
Vice President, Science Policy
Friends of Cancer Research

Track B - Day 2 PM

3:00 pm | Harmonization of Novel Biomarkers to Support Clinical Applications: TMB Case Study

Markus Zettl
Senior Director of Immuno–Oncology
Pieris Pharmaceuticals GmbH

Track B - Day 2 AM

11:30 am | The Use of Biomarkers to Confirm Mode of Action & Inform Combination Strategy for PRS-343 in Her2-Low Gastric Cancer in Combination with Tucatinib

Matt Davis
Director of NGS
Gritstone Bio

Track A - Day 1 AM

1:00 pm | Panel Discussion: What’s Needed to Move the Needle in IO?

Track B - Day 2 AM

12:30 pm | Evaluating Neoantigen Immunotherapies in the Clinic

Matthew Pink
Director, Business Development
Biodesix

Track C - Day 1 AM

12:00 pm | Utilizing a Multi-Omic Approach to Precision Medicine

Megan Ann Greenfield
Partner
McKinsey & Company

ED&I CDx Engage Workshop

Monday 27 September, 2021

11:30 am | Women in the Workplace Post COVID: Charting a Path Forward

Michael Fossel
President & Founder
Telocyte

Day One

Thursday 13th December 2018

4:00 pm | Panel Discussion: How to Know When a CDx & a Predictive Biomarker is Needed for a Drug

Track A - Day 1 AM

10:05 am |

Moving the Needle in Immuno-Oncology

Track A - Day 1 PM

2:00 pm | “Everything Works in Mice, Nothing Works in Humans”: How a Unified Systems Model can Enable Therapeutic Success

1:36 pm |

Novel Models to Progress from Preclinical

Michael Kiebish
Chief Precision Medicine Officer
BERG

Track A - Day 2 AM

12:40 pm | Reverse Engineering Translational Biomarkers For Novel Breast Cancer Subtypes

11:30 am | Driving Biomarker Discovery: The UK Biobank Pharma Proteomics Project

Michael Montalto
Chief Scientific Officer
PathAI Inc.

Michele Vendruscolo
Chief Scientific Officer
University of Cambridge & Wren Therapeutics

Day One

Thursday 13th December 2018

4:00 pm | Panel Discussion: How to Know When a CDx & a Predictive Biomarker is Needed for a Drug

Michelle Zhang
Senior Vice President, Translational Research & Early Development
Ikena Oncology

ED&I CDx Engage Workshop

Monday 27 September, 2021

10:00 am | Panel Discussion: From Making Your Pledge to Implementation: How Is Your Organization Embedding Diversity, Equity & Inclusion Across All Internal Layers?

Mike Tang
Senior Vice President & General Counsel
Agilent Technologies

ED&I CDx Engage Workshop

Monday 27 September, 2021

10:30 am | Panel Discussion: Resilience Through Equity: Taking D&I to the Next Level

Ming Sound Tsao
Professor & Senior Scientist
Princess Margaret Cancer Centre, University Health Network

Track A - Day 1 PM

3:00 pm | Utility of Patient-Derived Organoid & Xenograft Models in Lung Cancer Preclinical & Clinical Research

Nicholas Confuorto
Senior Director, Digital Spatial Profiling Business Unit, Global Marketing
NanoString

Track A - Day 1 AM

12:30 pm | Reverse Translation: Accelerating Biomarker Discovery Using GeoMx Digital Spatial Profiling

Nicolas Garreau de Loubresse
Director of Business Development
Nuprobe

Track A - Day 2 PM

3:00 pm | Ultra-sensitive Biomarker Assay Development for Translational Research & Precision Medicine

Nikki Martin
Director, Precision Medicine Initiatives
LUNGevity

Track C - Day 2 PM

2:00 pm | Identifying Clinician and Patient Barriers to Guideline-Concordant Biomarker Testing

Norbert Farkas
Founder & Managing Partner
Centivis

Track C - Day 2 PM

3:00 pm | Panel Discussion Demonstrating Clinical Utility to Engage with Payors & Secure Reimbursement

Paco Delgado
Senior Director of Project Leadership, Personalised Healthcare (PHC) Solutions
Roche Diagnostics Solutions

Padraig McDonnell
President, Agilent CrossLab Group
Agilent Technologies

ED&I CDx Engage Workshop

Monday 27 September, 2021

10:30 am | Panel Discussion: Resilience Through Equity: Taking D&I to the Next Level

Patrice Jimerson
Associate Vice President, Diversity & Inclusion
Agilent Technologies

ED&I CDx Engage Workshop

Monday 27 September, 2021

10:30 am | Panel Discussion: Resilience Through Equity: Taking D&I to the Next Level

Qing Kang-Fortner
Associate Director - Translational Medicine
Syros Pharmaceuticals

Track C - Day 1 AM

12:30 pm | Panel Discussion: Cross-Functional Communication

Qingyan Au
Principal Scientist, Director of Multiplexing Operations, Pharma
NeoGenomics Laboratories

Day One

Thursday 13th December 2018

5:00 pm | Pathways for Multiplexed IF: Development Through Clinical Trials & Commercialization Considerations

Raghavan Venugopal
Director of Imaging & Algorithms
Roche Diagnostics Solutions

Ralph Riley
Global Co Diagnostic Market Access Leader
Janssen

Raymond Kozikowski
Strategic Applications & Innovation Lab, Research & Early Development
Roche Diagnostics Solutions

Robert McCormack

Independent

Track B - Day 2 PM

2:30 pm | Liquid Biopsies in Cancer Drug Development & Clinical Use

Roman Yelensky
Executive Vice President & Chief Technology Officer
Gristone Bio

Roni Mamluk
Chief Executive Officer
Ayala Pharmaceuticals

Track B - Day 1 PM

2:30 pm | Data Driven Companion Diagnostic Development

Ross L. Levine
Chief of the Molecular Cancer Medicine Service (HOPP)
Memorial Sloan Kettering Cancer Center

Russell Garlick
Chief Scientific Officer
Seracare

Samik Basu
Vice President, Preclinical & Translational Research
Cabaletta Bio

ED&I CDx Engage Workshop

Monday 27 September, 2021

10:00 am | Panel Discussion: From Making Your Pledge to Implementation: How Is Your Organization Embedding Diversity, Equity & Inclusion Across All Internal Layers?

Sarah Hersey
Vice President, Precision Medicine
Bristol Myers Squibb

ED&I CDx Engage Workshop

Monday 27 September, 2021

10:00 am | Panel Discussion: From Making Your Pledge to Implementation: How Is Your Organization Embedding Diversity, Equity & Inclusion Across All Internal Layers?

Scott Bornheimer
Associate Director Medical & Scientific Affairs
BD Biosciences

Track C - Day 1 PM

2:40 pm | Panel Discussion: Flow Cytometry as a Tool for New Biomarkers and Companion Diagnostics Based on Single Cell Protein Expression

Scott Patterson
Vice President, Biomarker Sciences
Gilead Sciences

ED&I CDx Engage Workshop

Monday 27 September, 2021

12:00 pm | Transforming the Recruitment Process & Returning to Work in the Post-COVID19 Era – Further Accelerating Our Industry’s Journey to Becoming Truly Equal, Diverse & Inclusive

Senior Leader –

Leica Biosystems

Shane Olwill
Senior Vice President, Head of Translational Science
Pieris Pharmaceuticals GmbH

Track A - Day 1 AM

1:00 pm | Panel Discussion: What’s Needed to Move the Needle in IO?

Shirin Hasan
Associate Vice President, Head of Global Clinical Affairs
Agilent Technologies

ED&I CDx Engage Workshop

Monday 27 September, 2021

10:30 am | Panel Discussion: Resilience Through Equity: Taking D&I to the Next Level

Track C - Day 1 AM

11:00 am | Panel Discussion: A Shared Vision: Building a Best-in-Class Model for Global CDx Clinical Trial Deployment

Siddha Kasar
Associate Director, Clinical Translational Lead, Cell Therapies
Takeda

ED&I CDx Engage Workshop

Monday 27 September, 2021

12:00 pm | Transforming the Recruitment Process & Returning to Work in the Post-COVID19 Era – Further Accelerating Our Industry’s Journey to Becoming Truly Equal, Diverse & Inclusive

Simi Ahmed
Senior Vice President
The New York Stem Cell Foundation

ED&I CDx Engage Workshop

Monday 27 September, 2021

9:10 am | Round Table Discussion: Effective Leadership & Mentorship Structures to Foster Diversity & Inclusion Across Your Organization

Sri Venkatram
Director, CDx Strategy
AbbVie

Day One

Thursday 13th December 2018

4:00 pm | Panel Discussion: How to Know When a CDx & a Predictive Biomarker is Needed for a Drug

Stephane Wong
Immuno-Oncology Companion Diagnostics Senior Director
GlaxoSmithKline

Day One

Thursday 13th December 2018

5:30 pm | Jemperli: End-to-End Companion Diagnostic Co-Development Indicated for Adult Patients with Recurrent or Advanced dMMR Endometrial Cancer and Solid Tumors

Steve Anderson
Chief Scientific Officer & Senior Vice President
Labcorp Drug Development

Steve Anderson
Chief Scientific Officer
LabCorp Drug Development

Track C - Day 1 PM

2:40 pm | Panel Discussion: Flow Cytometry as a Tool for New Biomarkers and Companion Diagnostics Based on Single Cell Protein Expression

Track C - Day 2 PM

3:00 pm | Panel Discussion Demonstrating Clinical Utility to Engage with Payors & Secure Reimbursement

Steven Berman
Science Policy Analyst
US Food & Drug Administration

Track B - Day 1 AM

12:30 pm | Panel Discussion: Preparation & Planning for Regulatory Assessment

Susanne Munksted
Chief Precision Officer
Diaceutics

ED&I CDx Engage Workshop

Monday 27 September, 2021

12:30 pm | Remaining Connected During COVID – & Preparing The Organization for a Post-COVID Reality

Theresa Whiteside
Professor of Pathology, Immunology and Otolaryngology
UPMC Hillman Cancer Center, University of Pittsburgh Cancer Institute

Track B - Day 1 PM

3:00 pm | Tumor-Derived Small EVs (Exosomes) as Promising Biomarkers in Immuno-Oncology

Tim Forshew
Head of Science and Innovation & Co-Founder
Inivata

Track B - Day 2 PM

3:30 pm | Personalized ctDNA MRD Assays – Redefined

Tim Heffernan
Executive Director, Oncology Research
MD Anderson Cancer Center- Translational Research to Advance Therapeutics & Innovation in Oncology

Day One

Thursday 13th December 2018

8:00 am | Translational Case Study: Translational Development of IACS-6274, a Potent and Selective Glutaminase (GLS1) Inhibitor in Phase 1 Trials for Molecularly-Defined Subsets of Patients with Advanced Solid Tumors

Tom Defay
Deputy Head, Diagnostics Strategy & Development
Alexion Pharmaceuticals, Inc.

Day Two

Thursday 13th December 2018

10:30 am | Diagnostic Advances for Rare Diseases, Now, & in the Future

Tom Li
Head of Global Biopharma Business Development
Burning Rock Biotech

Track C - Day 1 PM

2:30 pm | Global Trials - Benefits of Utilizing a Single Assay Worldwide

Travis Hollman
Dermatopathologist Memorial Sloan
Kettering Cancer Center

Track A - Day 1 AM

11:00 am | Can Investigating the Tumor Microenvironment Help Better Understand Disease Drivers & Response?

Trevor Page
Chief Business Officer, Companion Diagnostics
Agilent Technologies

Track C - Day 1 AM

11:00 am | Panel Discussion: A Shared Vision: Building a Best-in-Class Model for Global CDx Clinical Trial Deployment

William Powell
Director Product Technology and Strategy
Leica Biosystems

Track A - Day 2 AM

12:10 pm | Building an Emerging Technologies Model from R&D to Commercialization by Leveraging Foundational Biomarkers and Clinical Dx Evidence

Zheng Feng
Director & Head of Molecular Biomarker & Genomics, Global Clinical Biomarkers & Companion Diagnostics
EMD Serono

ED&I CDx Engage Workshop

Monday 27 September, 2021

11:00 am | Panel Discussion: Diversity, Equity, & Inclusion: Why Does This Matter, and What Does It Mean for the Future of Healthcare?

Zisis Kozlakidis
Head of Laboratory Services and Biobanking
International Agency for Research on Cancer/World Health Organization (IARC/WHO)

Track A - Day 2 PM

3:30 pm | Biomarker Discovery and the Quality of Biological Samples